SC
RLAY icon

Schubert & Co’s Relay Therapeutics RLAY Stock Holding History

Schubert & Co’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11
Closed -$182 – 1193
2023
Q1 		$182 Buy
11
+10
+1,000% +$179 ﹤0.01% 1556
2022
Q4 		$15 Sell
1
-13
-93% -$249 ﹤0.01% 1632
2022
Q3 		$0 Buy
14
+8
+133% +$176 ﹤0.01% 1543
2022
Q2 		$0 Buy
+6
New +$129 ﹤0.01% 1567

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Schubert & Co's RLAY Position: Q2 2023 in Review

Schubert & Co sold out of Relay Therapeutics (RLAY) in Q2 2023, closing a stake of 11 shares — an estimated $182 sold.

Schubert & Co first reported a position in RLAY in Q2 2022 and held it in 4 quarters. The position peaked at $182 in Q1 2023. 161 funds tracked by Wall St. Rank hold RLAY as of Q2 2023.

  • Schubert & Co reported no remaining Relay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 11 Relay Therapeutics shares in Q2 2023, an estimated $182.
  • Schubert & Co first reported a position in Relay Therapeutics in Q2 2022 and held it in 4 quarters.
  • Schubert & Co's Relay Therapeutics position peaked at $182 in Q1 2023.
  • 161 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.